|
Imprimis Pharmaceuticals acquires license to patented formulation for dry eye disease
Imprimis Pharmaceuticals Inc , an ophthalmology-focused pharmaceutical company, announced that it has entered into an licensing agreement for the exclusive worldwide rights to Klarity...
|
|
Neurocrine Announces FDA Approval of INGREZZA TM Capsules
Neurocrine Biosciences, Inc. announced that the U.S. FDA has approved INGREZZATM (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD).INGREZZA, a novel, selective vesicular monoamine transporter...
|
|